Trifarotene
Trifarotene is a fourth-generation retinoid that is highly selective for retinoic acid receptor gamma (RARγ), the predominant RAR subtype in the skin, normalizing keratinocyte differentiation and proliferation with improved tolerability compared to less selective retinoids. It is approved as a topical cream for the treatment of acne vulgaris on the face and trunk, and is being investigated for other dermatological conditions. Its receptor selectivity reduces systemic and local retinoid-associated adverse effects compared to tretinoin.
분자량
459.6000 g/mol
LogP
6.30
TPSA
70.00 Ų
리핀스키 5의 법칙
통과
치료 영역
작용 기전
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
2D 구조
Cite this structure
Embed this structure
SMILES
CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
InChI
InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)
Molecular Formula
C29H33NO4
HBD / HBA
2 / 5
회전 가능 결합
8
무거운 원자
34
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
Trifarotene is a fourth-generation retinoid that is highly selective for retinoic acid receptor gamma (RARγ), the predominant RAR subtype in the skin, normalizing keratinocyte differentiation and proliferation with improved tolerability compared to less selective retinoids. It is approved as a topical cream for the treatment of acne vulgaris on the face and trunk, and is being investigated for other dermatological conditions. Its receptor selectivity reduces systemic and local retinoid-associated adverse effects compared to tretinoin.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Trifarotene is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3707313. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11518241. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trifarotene"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trifarotene/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trifarotene/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trifarotene/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trifarotene"></drugfyi-drug>